Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market

Behavioural Pharmacology

Volumn 26, Issue 5, 2015, Pages 460-468

  Gatch, Michael B ^a   Forster, Michael J ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

abuse liability; cannabinoids; drug discrimination; locomotor activity; mouse; rat

Indexed keywords

(1 PENTYLINDOL 3 YL) (2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; CANNABINOID; DRONABINOL; N (1 ADAMANTYL) 1 PENTYL 1H INDAZOLE 3 CARBOXAMIDE; N (1 AMINO 3 METHYL 1 OXOBUTAN 2 YL) 1 (4 FLUOROBENZYL) 1H INDAZOLE 3 CARBOXAMIDE; PSYCHOTROPIC AGENT; QUINOLIN 8 YL 1 (5 FLUOROPENTYL) 1H INDOLE 3 CARBOXYLATE; QUINOLIN 8 YL 1 PENTYL 1H INDOLE 3 CARBOXYLATE; UNCLASSIFIED DRUG; [1 (5 FLUORO PENTYL) 1H INDOL 3 YL](2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; (1-PENTYL-1H-INDOL-3-YL)(2,2,3,3-TETRAMETHYLCYCLOPROPYL)METHANONE; 1-PENTYL-1H-INDOLE-3-CARBOXYLIC ACID 8-QUINOLINYL ESTER; CENTRAL DEPRESSANT AGENT; INDOLE DERIVATIVE; QUINOLINE DERIVATIVE; STREET DRUG; XLR-11;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; LOCOMOTION; MALE; MOUSE; NONHUMAN; RAT; ANIMAL; DRUG EFFECTS; INSTRUMENTAL CONDITIONING; MOTOR ACTIVITY; PERCEPTIVE DISCRIMINATION; PRECLINICAL STUDY; SPRAGUE DAWLEY RAT;

ANIMALS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DRONABINOL; DRUG EVALUATION, PRECLINICAL; INDOLES; MALE; MICE; MOTOR ACTIVITY; PSYCHOTROPIC DRUGS; QUINOLINES; RATS, SPRAGUE-DAWLEY; STREET DRUGS;

EID: 84938809767     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000150     Document Type: Article

References (28)

1. Balster RL (1991). Drug abuse potential evaluation in animals. Br J Addict 86:1549-1558.
2. Behonick G, Shanks KG, Firchau DJ, Mathur G, Lynch CF, Nashelsky M, et al. (2014). Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol 38:559-562.
3. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, et al. (2012). Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol 83:952-961.
4. Buser GL, Gerona RR, Horowitz BZ, Vian KP, Troxell ML, Hendrickson RG, et al. (2014). Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol (Phila) 52:664-673.
5. Centers for Disease Control and Prevention (2013). Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morb Mortal Wkly Rep 62:93-98.
6. Drug Enforcement Administration (2013). Schedules of controlled substances: temporary placement of three synthetic cannabinoids into schedule I. Final order. Fed Regist 78:28735-28739.
7. Drug Enforcement Administration (2014a). Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order. Fed Regist 79:7577-7582.
8. Drug Enforcement Administration (2014b). National Forensic Laboratory Information System Special Report: synthetic cannabinoids and synthetic cathinones reported in NFLIS, 2010-2013, in US. Springfield, VA: Drug Enforcement Administration.
9. Fantegrossi WE, McCain KR, Moran JH, Hoffman RS (2013). Not simply synthetic tetrahydrocannabinol. J Pediatr 163:1797-1798.
10. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL (2014). Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to ? (9)-THC: mechanism underlying greater toxicity? Life Sci 97:45-54.
11. Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, et al. (2010). Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem 53:295-315.
12. Gatch MB, Forster MJ (2014). Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice. Behav Pharmacol 25:750-757.
13. Gatch MB, Taylor CM, Forster MJ (2013). Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones. Behav Pharmacol 24:437-447.
14. Gatch MB, Rutledge MA, Forster MJ (2015). Discriminative and locomotor effects of five synthetic cathinones in rats and mice. Psychopharmacology (Berl) 232:1197-1205.
15. Ginsburg BC, Schulze DR, Hruba L, McMahon LR (2012). JWH-018 and JWH-073: Δ9-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther 340:37-45.
16. Gugelmann H, Gerona R, Li C, Tsutaoka B, Olson KR, Lung D (2014). 'Crazy Monkey' poisons man and dog: human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol (Phila) 52:635-638.
17. Horton DB, Potter DM, Mead AN (2013). A translational pharmacology approach to understanding the predictive value of abuse potential assessments. Behav Pharmacol 24:410-436.
18. Järbe TU, Deng H, Vadivel SK, Makriyannis A (2011). Cannabinergic aminoalkylindoles, including AM678 =JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol 22:498-507.
19. Kavanagh P, Grigoryev A, Savchuk S, Mikhura I, Formanovsky A (2013). UR-144 in products sold via the Internet: identification of related compounds and characterization of pyrolysis products. Drug Test Anal 5:683-692.
20. Lemos NP (2014). Driving under the influence of synthetic cannabinoid receptor agonist XLR-11. J Forensic Sci 59:1679-1683.
21. Mohr AL, Ofsa B, Keil AM, Simon JR, McMullin M, Logan BK (2014). Enzymelinked immunosorbent assay (ELISA) for the detection of use of the synthetic cannabinoid agonists UR-144 and XLR-11 in human urine. J Anal Toxicol 38:427-431.
22. Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kneisel S, Hutter M, Auwärter V (2014). Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int J Legal Med 128:59-64.
23. National Research Council (2011). Guide for the Care and Use of Laboratory Animals. Washington, DC: The National Academies Press.
24. Strano Rossi S, Odoardi S, Gregori A, Peluso G, Ripani L, Ortar G, et al. (2014). An analytical approach to the forensic identification of different classes of new psychoactive substances (NPSs) in seized materials. Rapid Commun Mass Spectrom 28:1904-1916.
25. Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2013). URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 227:21-32.
26. Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, Martin BR (1998). Structure-activity relationships of indole-and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 285:995-1004.
27. Wiley JL, Marusich JA, Lefever TW, Grabenauer M, Moore KN, Thomas BF (2013). Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology 75: 145-154.
28. Wiley JL, Lefever TW, Cortes RA, Marusich JA (2014). Cross-substitution of Δ(9)-tetrahydrocannabinol and JWH-018 in drug discrimination in rats. Pharmacol Biochem Behav 124:123-128.